CN105308101B - 具有s形释放曲线的聚丙交酯-聚乙交酯微粒的制备 - Google Patents

具有s形释放曲线的聚丙交酯-聚乙交酯微粒的制备 Download PDF

Info

Publication number
CN105308101B
CN105308101B CN201480034979.2A CN201480034979A CN105308101B CN 105308101 B CN105308101 B CN 105308101B CN 201480034979 A CN201480034979 A CN 201480034979A CN 105308101 B CN105308101 B CN 105308101B
Authority
CN
China
Prior art keywords
phase
particle
risperidone
polymer
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480034979.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105308101A (zh
Inventor
E·卡拉瓦斯
E·科特里斯
S·海蒂都尔
T·曼特尔丽萨
G·帕帕尼古拉乌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmathen SA
Original Assignee
Pharmathen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen SA filed Critical Pharmathen SA
Publication of CN105308101A publication Critical patent/CN105308101A/zh
Application granted granted Critical
Publication of CN105308101B publication Critical patent/CN105308101B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2300/00—Characterised by the use of unspecified polymers
    • C08J2300/16—Biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480034979.2A 2013-06-20 2014-06-18 具有s形释放曲线的聚丙交酯-聚乙交酯微粒的制备 Active CN105308101B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/001821 2013-06-20
EP2013001821 2013-06-20
PCT/EP2014/001652 WO2014202214A1 (en) 2013-06-20 2014-06-18 Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile

Publications (2)

Publication Number Publication Date
CN105308101A CN105308101A (zh) 2016-02-03
CN105308101B true CN105308101B (zh) 2018-10-23

Family

ID=51022802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480034979.2A Active CN105308101B (zh) 2013-06-20 2014-06-18 具有s形释放曲线的聚丙交酯-聚乙交酯微粒的制备

Country Status (15)

Country Link
US (1) US9943484B2 (enExample)
JP (1) JP6464154B2 (enExample)
CN (1) CN105308101B (enExample)
AU (1) AU2014283692B2 (enExample)
CA (1) CA2916301C (enExample)
DK (1) DK3010962T4 (enExample)
ES (1) ES2640486T5 (enExample)
FI (1) FI3010962T4 (enExample)
HU (1) HUE036141T2 (enExample)
LT (1) LT3010962T (enExample)
PT (1) PT3010962T (enExample)
RU (1) RU2658004C2 (enExample)
SA (1) SA515370296B1 (enExample)
WO (1) WO2014202214A1 (enExample)
ZA (1) ZA201509354B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2774359T3 (es) 2014-07-30 2020-07-20 Merck Patent Gmbh Composición que puede comprimirse directamente que contiene celulosa microcristalina
JP2016102093A (ja) * 2014-11-28 2016-06-02 ニプロ株式会社 塩基性の求核化合物を含有するマイクロカプセルの製造方法
ES2960753T3 (es) 2015-09-21 2024-03-06 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
GR1009870B (el) * 2019-07-09 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου
JP7550474B2 (ja) * 2019-12-31 2024-09-13 広州帝奇医薬技術有限公司 第３級アミン医薬組成物の工業化バッチ調製方法
EP4125823A1 (en) 2020-03-30 2023-02-08 Biological E Limited Risperidone microspheres, process for their prepartion and uses thereof
KR102259589B1 (ko) * 2020-11-30 2021-06-02 (주)인벤티지랩 미소구체 제조 시스템 및 미소구체 제조 방법
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
KR20230157365A (ko) * 2021-02-24 2023-11-16 오크우드 레버러토리즈, 엘엘씨 루라시돈을 포함하는 마이크로스피어 제제 및 이의 제조 및 사용 방법
CN118284414A (zh) 2021-07-06 2024-07-02 M·哈斯莱顿 血清素再摄取抑制剂戒断综合征的治疗
GR1010327B (el) * 2021-10-06 2022-10-17 Φαρματεν Α.Β.Ε.Ε., Παρατεταμενης αποδεσμευσης ενεσιμο φαρμακευτικο σκευασμα λεβοθυροξινης και μεθοδος παρασκευης αυτου
WO2025135778A1 (ko) * 2023-12-18 2025-06-26 주식회사 포스테라헬스사이언스 약물의 특성에 따른 활성형 미립자의 제조 방법, 이의 제조 방법으로 제조된 활성형 미립자 및 상기 활성형 미립자를 이용한 약물을 포함하는 장기 지속 제형의 제조 방법
WO2025207396A1 (en) * 2024-03-27 2025-10-02 Avidence Therapeutics, Inc. Microsphere-based injectable rofecoxib formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1226821A (zh) * 1996-05-07 1999-08-25 阿尔克迈斯控制医疗第二公司 微颗粒
WO2000040221A1 (en) * 1998-12-30 2000-07-13 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
BR9607752B1 (pt) * 1996-01-24 2009-05-05 formulação farmacêutica de microcápsula de liberação controlada.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7690026B2 (en) * 2005-08-22 2010-03-30 Microsoft Corporation Distributed single sign-on service

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1226821A (zh) * 1996-05-07 1999-08-25 阿尔克迈斯控制医疗第二公司 微颗粒
WO2000040221A1 (en) * 1998-12-30 2000-07-13 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile

Also Published As

Publication number Publication date
RU2658004C2 (ru) 2018-06-19
RU2016101418A (ru) 2017-07-25
HUE036141T2 (hu) 2018-06-28
AU2014283692B2 (en) 2017-04-27
SA515370296B1 (ar) 2017-10-12
ES2640486T3 (es) 2017-11-03
US20160143851A1 (en) 2016-05-26
JP6464154B2 (ja) 2019-02-06
CA2916301C (en) 2020-01-07
DK3010962T3 (en) 2017-10-23
FI3010962T4 (fi) 2023-05-04
WO2014202214A1 (en) 2014-12-24
ES2640486T5 (es) 2023-04-28
US9943484B2 (en) 2018-04-17
JP2017507895A (ja) 2017-03-23
PT3010962T (pt) 2017-09-05
CN105308101A (zh) 2016-02-03
AU2014283692A1 (en) 2016-01-21
DK3010962T4 (da) 2023-04-17
CA2916301A1 (en) 2014-12-24
ZA201509354B (en) 2017-07-26
LT3010962T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
CN105308101B (zh) 具有s形释放曲线的聚丙交酯-聚乙交酯微粒的制备
De Rosa et al. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres
Jain et al. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables
EP1925297B2 (en) Method for preparing microparticles having a selected polymer molecular weight
AU2004277419B2 (en) Nanoparticulate therapeutic biologically active agents
Yeo et al. A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange
Dinarvand et al. Effect of surfactant HLB and different formulation variables on the properties of poly-D, L-lactide microspheres of naltrexone prepared by double emulsion technique
D'Souza et al. Methods to assess in vitro drug release from injectable polymeric particulate systems
Rosca et al. Microparticle formation and its mechanism in single and double emulsion solvent evaporation
EP2595606B1 (en) Method for preparing microspheres and microspheres produced thereby
EP3125871B1 (en) Preparation of peptide loaded plga microspheres with controlled release characteristics
Dong et al. Stability of poly (D, L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems
Lu et al. Microparticles produced by the hydrogel template method for sustained drug delivery
FR2691631A1 (fr) Compositions contenant des sels de peptides formés avec des polyesters à terminaison carboxy et procédés pour leur production.
Hu et al. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres
Xiao et al. The effect of polymer blends on initial release regulation and in vitro-in vivo relationship of peptides loaded PLGA-Hydrogel Microspheres
Ahmed et al. Reduction in burst release of PLGA microparticles by incorporation into cubic phase-forming systems
EP3785704B1 (en) Method for preparing biodegradable microsheres using stabilized single-phase mixed solution
WO2016019881A1 (en) Process for the preparation of sustained-release microparticles having a controllable release profile
US20110236496A1 (en) Emulsions for Microencapsulation Comprising Biodegradable Surface-Active Block Copolymers as Stabilizers
EP3010962B2 (en) Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
Philo et al. Formulation and evaluation of octreotide acetate loaded PLGA microspheres

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant